Commercialization
A number of public and private companies are competing to develop a full genome sequencing platform that is commercially robust for both research and clinical use, including: Illumina Knome Sequenom, 454 Life Sciences, Pacific Biosciences Complete Genomics, Helicos Biosciences, GE Global Research (General Electric), Affymetrix, AQI Sciences, Base4, Callida Genomics, CrackerBio Dover Systems Electron Optica Electronic BioSciences Full Genomes, Genia Technologies Genizon Biosciences GenoVoxx, GnuBio, Halcyon Molecular, IBM, Intelligent Bio-Systems, LaserGen, Li-Cor, LingVitae Life Technologies, LightSpeed Genomics, Mobious Genomics, NABsys, Nanophotonics Biosciences, NetBio, Noblegen Biosciences, Oxford Nanopore Technologies Population Genetics, Reveo, Seirad, PathoGenetix, VisiGen Biotechnologies, ZS Genetics, and BioNano Genomics These companies are heavily financed and backed by venture capitalists, hedge funds, and investment banks.
Read more about this topic: Whole Genome Sequencing